NASDAQ$CODX
Co-Diagnostics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Co-Diagnostics reported its financial results for the first quarter ended March 31, 2025.
Co-Diagnostics reported a significant decrease in revenue for Q1 2025, primarily due to the timing of grant revenue recognition, with total revenue at $0.1 million. Despite this, the company managed to reduce its operating expenses and net loss compared to the prior year, while maintaining a healthy cash position.
- Revenue for Q1 2025 was $0.1 million, a decrease from $0.5 million in Q1 2024.
- Operating expenses decreased by 18.2% to $8.6 million compared to the prior year first quarter.
- Net loss improved to $7.5 million, or $0.24 per fully diluted share, from $9.3 million, or $0.31 per fully diluted share, in Q1 2024.
- Cash, cash equivalents, and marketable securities stood at $21.5 million as of March 31, 2025.
Headline financials
Revenue & EPS history
Co-Diagnostics · Revenue · Quarterly
$50.3K
Revenue by segment
Co-Diagnostics · $146K total across 1 segment · Q1 2026
- Product$146K—100.0%
Forward guidance
Co-Diagnostics remains focused on advancing its PCR platform to market, with clinical evaluations and regulatory submissions for key tests underway, and manufacturing facility completion in India by year-end 2025.
Tailwinds
- Remain on track for initiation of clinical evaluations for 4 tests in product pipeline.
- Completion of manufacturing facility in India by year-end 2025.
- Advancing towards clinical evaluations and regulatory submissions for the 4 main tests in the pipeline.
- Belief that the Co-Dx PCR platform will play a key role in transforming global accessibility of diagnostic testing solutions.
- Maintaining operational efficiency while advancing towards several development milestones.
Headwinds
- The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
- No specific revenue guidance provided for future periods.
- Reliance on timely completion of clinical evaluations and regulatory approvals.
- Potential for inherent uncertainties, risks, and changes in circumstances to affect actual results.
- No specific negative forward-looking statements were made in the report, but general risks associated with regulatory approvals and market adoption apply.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-5.3%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.4%
Avg return
30 days after
34%
12 / 35 earnings
Positive
+21.0%
Q1 2022
Best reaction
-32.3%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +24.4% | — | |
| Q3 2025 | -11.4% | -8.1% | -8.3% | |
| Q2 2025 | +11.7% | +6.4% | +28.7% | |
| Q1 2025 | -2.4% | -2.8% | -15.5% | |
| Q4 2024 | -18.3% | -8.7% | -10.7% | |
| Q3 2024 | -5.8% | -3.3% | -29.7% | |
| Q2 2024 | +4.7% | +9.3% | +25.2% | |
| Q1 2024 | -9.0% | -8.2% | +10.7% | |
| Q4 2023 | -9.3% | -6.8% | +1.7% | |
| Q3 2023 | -7.3% | +9.8% | -0.8% | |
| Q2 2023 | -10.8% | -6.9% | -5.4% | |
| Q1 2023 | +0.8% | +4.9% | -20.9% | |
| Q4 2022 | -14.8% | -34.4% | -46.4% | |
| Q3 2022 | +8.6% | +9.7% | -17.4% | |
| Q2 2022 | -32.3% | -37.9% | -50.6% | |
| Q1 2022 | +21.0% | +33.8% | +35.1% | |
| Q4 2021 | -8.3% | +4.0% | -24.4% | |
| Q3 2021 | +7.8% | +13.1% | -2.3% | |
| Q2 2021 | +11.0% | +15.6% | +10.8% | |
| Q1 2021 | +15.7% | +20.4% | +20.8% | |
| Q4 2020 | -21.8% | -31.1% | -27.8% | |
| Q3 2020 | -20.6% | -26.0% | -28.8% | |
| Q2 2020 | -16.8% | -21.2% | -29.9% | |
| Q1 2020 | -27.1% | -19.5% | -33.5% | |
| Q4 2019 | -16.7% | -10.4% | +35.2% | |
| Q3 2019 | -4.3% | -3.9% | +7.1% | |
| Q2 2019 | -11.1% | -8.1% | -13.5% | |
| Q1 2019 | -14.2% | -20.3% | -25.7% | |
| Q4 2018 | +5.6% | +0.0% | -8.2% | |
| Q3 2018 | +2.3% | -9.3% | -13.1% | |
| Q2 2018 | -1.4% | -4.5% | -10.8% | |
| Q1 2018 | -8.1% | -7.0% | +129.7% | |
| Q4 2017 | -5.9% | -11.3% | -14.9% | |
| Q3 2017 | -3.2% | -6.8% | -43.4% | |
| Q2 2017 | +3.2% | +9.4% | +29.0% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro